Meeting
2019 ASCO Annual Meeting
First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
Authors
Masatoshi Kudo
Kindai University, Faculty of Medicine, Osaka, Japan
Masatoshi Kudo , Kenta Motomura , Yoshiyuki Wada , Yoshitaka Inaba , Yasunari Sakamoto , Masayuki Kurosaki , Yoshiko Umeyama , Yoichi Kamei , Junichiro Yoshimitsu , Yosuke Fujii , Mana Aizawa , Paul B. Robbins , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03289533
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4072)
DOI
10.1200/JCO.2019.37.15_suppl.4072
Abstract #
4072
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).
First Author: Toni K. Choueiri
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
First Author: James M. G. Larkin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
First Author: Richard S. Finn
Poster
2020 ASCO Virtual Scientific Program
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
First Author: Benjamin Maurice Solomon